These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

535 related articles for article (PubMed ID: 24857402)

  • 1. A systematic review, psychometric analysis and qualitative assessment of generic preference-based measures of health in mental health populations and the estimation of mapping functions from widely used specific measures.
    Brazier J; Connell J; Papaioannou D; Mukuria C; Mulhern B; Peasgood T; Jones ML; Paisley S; O'Cathain A; Barkham M; Knapp M; Byford S; Gilbody S; Parry G
    Health Technol Assess; 2014 May; 18(34):vii-viii, xiii-xxv, 1-188. PubMed ID: 24857402
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Use of generic and condition-specific measures of health-related quality of life in NICE decision-making: a systematic review, statistical modelling and survey.
    Longworth L; Yang Y; Young T; Mulhern B; Hernández Alava M; Mukuria C; Rowen D; Tosh J; Tsuchiya A; Evans P; Devianee Keetharuth A; Brazier J
    Health Technol Assess; 2014 Feb; 18(9):1-224. PubMed ID: 24524660
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Developing and testing methods for deriving preference-based measures of health from condition-specific measures (and other patient-based measures of outcome).
    Brazier JE; Rowen D; Mavranezouli I; Tsuchiya A; Young T; Yang Y; Barkham M; Ibbotson R
    Health Technol Assess; 2012 Jul; 16(32):1-114. PubMed ID: 22832015
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Using generic preference-based measures in mental health: psychometric validity of the EQ-5D and SF-6D.
    Mulhern B; Mukuria C; Barkham M; Knapp M; Byford S; Soeteman D; Brazier J
    Br J Psychiatry; 2014 Sep; 205(3):236-43. PubMed ID: 24855127
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A review of the psychometric properties of generic utility measures in multiple sclerosis.
    Kuspinar A; Mayo NE
    Pharmacoeconomics; 2014 Aug; 32(8):759-73. PubMed ID: 24846760
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Assessment of health-related quality of life in individuals with depressive symptoms: validity and responsiveness of the EQ-5D-3L and the SF-6D.
    Stolz M; Albus C; Beutel ME; Deter HC; Fritzsche K; Herrmann-Lingen C; Michal M; Petrowski K; Ronel J; Schultz JH; Söllner W; Weber C; de Zwaan M; Krauth C
    Eur J Health Econ; 2023 Nov; 24(8):1297-1307. PubMed ID: 36385438
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A head-to-head comparison of EQ-5D-5L and SF-6D in Dutch patients with fractures visiting a Fracture Liaison Service.
    Li N; Boonen A; van den Bergh JP; van Kuijk SMJ; Wyers CE; van Oostwaard M; Vranken L; Bours SPG; Hiligsmann M
    J Med Econ; 2022; 25(1):829-839. PubMed ID: 35674412
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Psychometric performance of the CFQ-R-8D compared to the EQ-5D-3L and SF-6D in people with cystic fibrosis.
    Mukuria C; Rowen D; Acaster S; McGarry LJ; Lou Y; Sosnay PR; Quittner AL
    J Patient Rep Outcomes; 2024 Feb; 8(1):24. PubMed ID: 38416239
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Interchangeability of the EQ-5D and the SF-6D, and comparison of their psychometric properties in a spinal postoperative Spanish population.
    Selva-Sevilla C; Ferrara P; Gerónimo-Pardo M
    Eur J Health Econ; 2020 Jun; 21(4):649-662. PubMed ID: 32065301
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Measuring quality of life in mental health: are we asking the right questions?
    Connell J; O'Cathain A; Brazier J
    Soc Sci Med; 2014 Nov; 120():12-20. PubMed ID: 25194472
    [TBL] [Abstract][Full Text] [Related]  

  • 11. EQ-5D-5L and SF-6D Utility Measures in Symptomatic benign Thyroid Nodules: Acceptability and Psychometric Evaluation.
    Wong CKH; Lang BHH; Yu HMS; Lam CLK
    Patient; 2017 Aug; 10(4):447-454. PubMed ID: 28224296
    [TBL] [Abstract][Full Text] [Related]  

  • 12. How valid and responsive are generic health status measures, such as EQ-5D and SF-36, in schizophrenia? A systematic review.
    Papaioannou D; Brazier J; Parry G
    Value Health; 2011; 14(6):907-20. PubMed ID: 21914513
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Estimating the relationship between preference-based generic utility instruments and disease-specific quality-of-life measures in severe chronic constipation: challenges in practice.
    Parker M; Haycox A; Graves J
    Pharmacoeconomics; 2011 Aug; 29(8):719-30. PubMed ID: 21635017
    [TBL] [Abstract][Full Text] [Related]  

  • 14. EQ-5D in skin conditions: an assessment of validity and responsiveness.
    Yang Y; Brazier J; Longworth L
    Eur J Health Econ; 2015 Dec; 16(9):927-39. PubMed ID: 25358263
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Psychometric properties of the EuroQol-5D and Short Form-6D in patients with systemic lupus erythematosus.
    Aggarwal R; Wilke CT; Pickard AS; Vats V; Mikolaitis R; Fogg L; Block JA; Jolly M
    J Rheumatol; 2009 Jun; 36(6):1209-16. PubMed ID: 19369452
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Validation and comparison of EuroQoL-5 dimension (EQ-5D) and Short Form-6 dimension (SF-6D) among stable angina patients.
    Wu J; Han Y; Zhao FL; Zhou J; Chen Z; Sun H
    Health Qual Life Outcomes; 2014 Oct; 12():156. PubMed ID: 25343944
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Differential Psychometric Properties of EuroQoL 5-Dimension 5-Level and Short-Form 6-Dimension Utility Measures in Low Back Pain.
    Cheung PWH; Wong CKH; Cheung JPY
    Spine (Phila Pa 1976); 2019 Jun; 44(11):E679-E686. PubMed ID: 30475342
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Psychometric properties of Patient Reported Outcome Measures (PROMs) in patients diagnosed with Acute Respiratory Distress Syndrome (ARDS).
    Shah HA; Dritsaki M; Pink J; Petrou S
    Health Qual Life Outcomes; 2016 Jan; 14():15. PubMed ID: 26818098
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Responsiveness and minimally important difference of SF-6D and EQ-5D utility scores for the treatment of pelvic organ prolapse.
    Harvie HS; Honeycutt AA; Neuwahl SJ; Barber MD; Richter HE; Visco AG; Sung VW; Shepherd JP; Rogers RG; Jakus-Waldman S; Mazloomdoost D;
    Am J Obstet Gynecol; 2019 Mar; 220(3):265.e1-265.e11. PubMed ID: 30471259
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Using the Multiple Sclerosis Impact Scale to estimate health state utility values: mapping from the MSIS-29, version 2, to the EQ-5D and the SF-6D.
    Hawton A; Green C; Telford C; Zajicek J; Wright D
    Value Health; 2012 Dec; 15(8):1084-91. PubMed ID: 23244811
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 27.